Non-steady state population kinetics of intravenous phenytoin

Therapeutic Drug Monitoring

Volumn 20, Issue 4, 1998, Pages 408-416

  Frame, Bill ^a   Beal, Stuart L ^b  

^a Metro Health Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Hybrid first order conditional estimation; Induction; Michaelis Menten elimination; Nonlinear mixed effects model; NONMEM; Phenytoin; Population pharmacokinetics

Indexed keywords

PHENYTOIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MONITORING; DRUG PROTEIN BINDING; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MICHAELIS CONSTANT; POLYPHARMACY; PRIORITY JOURNAL; SEIZURE;

AGED; ANTICONVULSANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INJECTIONS, INTRAVENOUS; MATHEMATICAL COMPUTING; MIDDLE AGED; MODELS, BIOLOGICAL; MODELS, STATISTICAL; PHENYTOIN; RETROSPECTIVE STUDIES;

EID: 0031874108     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199808000-00010     Document Type: Article

References (18)

1. Grasela TH, Sheiner LB, Rambeck B, et al. Steady-state pharmacokinetics of phenytoin from routinely collected patient data. Clin Pharmacokinel 1983;8;355-64.
2. Odani A, Hashimoto Y, Takayanagi K, et al. Population pharmacokinetics of phenytoin in Japanese patients with epilepsy: analysis with a dose-dependent clearance model. Biol Pharm Bull 1996;19:444-8.
3. Mawer GE, Mullen PW, Rodgers M, Robins AJ, Lucas SB. Phenytoin dose adjustment in epileptic patients. Br J Clin Pharmacol 1974;1;163-8.
4. Allen JP, Ludden TM, Burrow SR, Clementi WA, Stavchansky SA. Phenytoin cumulation kinetics. Clin Pharmacol Ther 1979;26;445-8.
5. Ludden TM, Allen JP, Valutsky WA, et al. Individualization of phenytoin dosage regimens. Clin Pharmacol Ther 1977;21;287-93.
6. Boucher BA, Rodman JH, Jaresko GS, Rasmussen SN, Watridge CB, Fabian TC. Phenytoin pharmacokinetics in critically ill trauma patients. Clin Pharmacol Ther 1988;44;675-83.
7. Markowsky SJ, Skaar DJ, Christie JM, Eyer SD, Ehresman DJ. Phenytoin protein binding and dosage requirements during acute and convalescent phases following brain injury. Ann Pharmacother 1996;30;443-8.
8. Leppik IE, Fisher J, Kriel R, Sawchuk RJ. Altered phenytoin clearance with febrile illness. Neurology 1986;36;1367-70.
9. Evans WE, Schentag JJ, Jusko WJ. Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring. 2nd ed. Spokane: Applied Therapeutics; 1986:493-539.
10. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16;31-41.
11. NONMEM Project Group. NONMEM Users Guide. Beal SL, Sheiner LB, eds. San Francisco: University of California at San Francisco; 1992.
12. Beal SL. Computation of the explicit solution to the Michaelis-Menten equation. J Pharmacokinet Biopharm 1983;11:641-657.
13. NONMEM Project Group. NONMEM users Guide VII: Conditional Estimation Methods. Beal SL, Sheiner LB, eds. San Francisco: University of California at San Francisco; 1998.
14. Cadle RM, Zenon GJ, Rodriguez-Barradas MC, Hamill RJ. Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother 1994;28;191-5.
15. Levy RH, Mattson RH, Meldrum BS. Antiepileptic Drugs. 4th ed. New York: Raven Press, 1995; 315-38.
16. Liponi DF, Winter ME, Tozer TN. Renal function and therapeutic concentrations of phenytoin. Neurology 1984;34;395-7.
17. Dasgupta A, Dennen DA, Dean R, McLawhon RW. Displacement of phenytoin from serum protein carriers by antibiotics: studies with ceftriaxone, nafcillin, and sulfamethoxazole. Clin Chem 1991;37;98-100.
18. Hashimoto Y, Koue T, Otsuki Y, Yasuhara M, Hori R, Inui K. Simulation for population analysis of Michaelis-Menten kinetics. J Pharmacokinet Biopharm 1995;23;205-16.